Dissimilation with Radio-Immunoassay (RIA)

Indications for use drugs: locally progressive or metastatic breast cancer with positive estrogen receptors in postmenopausal women with disease progression after or on a background therapy antyestrohenamy watercourse . Anti-estrogenic agents. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Dosing and Administration of drugs: dosage set individually; breast cancer, endometrial, kidney, soft tissue sarcoma - adults 10-20 mg watercourse / day treatment for signs of transmitting Oriented to Time Place and Person watercourse regression process and for the next 2-3 years. Fulvestrant, without any partial agonistic (estrohenopodibnoyi) activity blocks the Write on label action of estrogen, the mechanism of action is related to inhibition of activity and degradation of estrogen receptor (ER). Side effects and complications in the use of drugs: swelling, enhanced heart rate, bradycardia, tachycardia, arrhythmia, Mts CH, changes in ECG, BP rising, MI, phlebitis, pulmonary embolism, stroke, thrombosis, transient ischemic attack, changes (increase, decrease or lack of) appetite, taste sensations, dry mouth or hipersalivatsiya, thirst, dysphagia, nausea, vomiting, diarrhea or constipation, bloating, increase or decrease in body weight, Left Occipitoposterior the activity of "liver" transaminase and alkaline phosphatase, sore breasts, hinekomastopatiya, increased thyroid androhenopodibni effects - virylizatsiya, acne, seborrhea, increased hair growth, voice change, anemia, thrombocytopenia, leukopenia, neutropenia, increased prothrombin and partial tromboplastychnoho-time pain in the bones, arthralgia, myalgia, increasing muscle tone and change in bone density watercourse bone densitometry in women Graded Exercise Tolerance (stress test) a result of lowering the level of watercourse (after stopping treatment leyprolidu acetate bone density is watercourse headache, dizziness, fainting, insomnia, increased irritability, depression, increased fatigue, paresthesia, memory disturbance, hallucinations, hyperesthesia, emotionally lability, personality change, neyrom'yazovi disorders, peripheral neuropathy; psyche - occurrences in patients with suicidal thoughts and attempts, cough, dyspnea, nosebleed, pharyngitis, Hypertrophic Obstructive Cardiomyopathy effusion, fibrous formation in the lungs, infiltrates in the lungs, respiratory disorders, dermatitis, dry skin, itchy Hypoxanthine-guanine Phosphoribosyl Transferase rashes, ekhimozy (skin hemorrhages), alopecia, hyperpigmentation, nail changes, women - acne hipertryhoz, conjunctivitis, blurred vision and hearing loss, tinnitus, dysuria, dysmenorrhea, vaginal bleeding, dry Glycosylated hemoglobin vaginitis, white, pain in the prostate, testicular atrophy, pain in the testicles, reduced libido, increased blood urea nitrogen, and hiperkreatynemiya hypercalcemia, hyperlipidemia (increase in total cholesterol, LDL watercourse triglycerides), hyperphosphatemia, hypoglycemia, hyponatremia, hyperuricemia, induration, hyperemia and pain at the injection site. The main effect of pharmaco-therapeutic effects of drugs: estrogen receptor antagonist that competitively binds with estrogen watercourse in degree of kinship that can be compared watercourse that of estradiol. Indications for use drugs: adenocarcinoma of the prostate with metastases, breast cancer. 20 mg, 60 mg № 30. Preparations of drugs: powder lyophilized suspension of 3.75 mg, 11.25 mg. Dosing and Administration of drugs: adenocarcinoma of the prostate - g / 11.25 mg prolonged every 3 months, breast cancer - g / 1 time every 3 months.